SPECIALIZED CENTER OF RESEARCH IN ARTERIOSCLEROSIS

这个SCOR项目的目标是在七个项目中阐明， 血浆脂蛋白与动脉粥样硬化的关系 对等离子体结构和功能的广泛研究 脂蛋白在正常情况下和在与 加速动脉粥样硬化的形成。 1)载脂蛋白的结构和功能：本项目将 研究的物理结构和功能域 载脂蛋白B，确定了几个新发现的结构 载脂蛋白和洗脱液中脂蛋白的结构 动脉粥样硬化斑块。 2)反向催化蛋白的结构-功能关系 胆固醇转运途径：该项目将利用定点定向 突变以阐明这些关键基因中功能上的重要区域 胆固醇反向运输的蛋白质，通过这种蛋白质，胆固醇是 从动脉粥样硬化斑块中去除。 3)肝细胞组装新生血浆脂蛋白：本项目 将阐明潜在的致动脉粥样硬化和 肝脏中的抗动脉粥样硬化脂蛋白。 4)肝脏在脂蛋白分解代谢中的作用：本项目将 阐明致动脉粥样硬化性脂蛋白从 血液和这些过程的调节。项目3和4可能 导致新的方法来调节致动脉粥样硬化和 血液中的抗动脉粥样硬化脂蛋白。 5)反向胆固醇运输和动脉壁：这个项目 将决定高密度脂蛋白的种类如何吸收和 酯化细胞和血浆胆固醇，并将其传递给其他脂蛋白 以供肝脏取出，并将促进我们对 从动脉壁中清除胆固醇的机制。 6)遗传性血脂异常：基因组决定因素和功能性 结果：本项目通过阐明家族性遗传病的基因组机制 血脂异常及其对脂蛋白的影响 相互转化和分解代谢，将增加我们对 致动脉粥样硬化性血脂异常的基础。 7)冠心病患者的餐后脂代谢：该项目 将调查血浆甘油三酯和胆固醇的异常 餐后状态中的运输提供了对 致动脉粥样硬化和抗动脉粥样硬化代谢的动态变化 脂肪摄入后的脂蛋白。SCOR将由三名工作人员提供支持 核心单位：一个血脂诊所、实验室和一个行政单位。 整个计划将形成一个凝聚力和连贯的攻击中心 血浆脂蛋白与动脉粥样硬化关系的研究进展。

The objective of this SCOR program is to elucidate, in seven projects, the relationship between plasma lipoproteins and atherosclerosis by a broad range of investigations of the structure and function of the plasma lipoproteins under normal conditions and in states associated with accelerated atherogenesis. 1) Structure and function of apolipoproteins: This Project will investigate the physical structure and functional domains of apolipoprotein B, determine the structure of several newly recognized apolipoproteins, and the structure of lipoproteins eluted from atherosclerotic plaques. 2) Structure-function relationships of catalytic proteins in the reverse cholesterol transport pathway: This Project will utilize site-directed mutagenesis to elucidate functionally important regions in these key proteins of reverse cholesterol transport, by which cholesterol is removed from atherosclerotic plaques. 3) Assembly of nascent plasma lipoproteins by hepatocytes: This Project will elucidate the steps in the assembly of potentially atherogenic and antiatherogenic lipoproteins in the liver. 4) Role of the liver in lipoprotein catabolism: This Project will elucidate mechanisms by which atherogenic lipoproteins are removed from the blood and the regulation of these processes. Projects 3 and 4 may lead to new approaches to regulate the concentration of atherogenic and antiatherogenic lipoproteins in the blood. 5) Reverse cholesterol transport and the arterial wall: This Project will determine how species of high density lipoproteins take up and esterify cell and plasma cholesterol and deliver it to other lipoproteins for removal by the liver, and will advance our understanding of the mechanisms by which cholesterol is removed from arterial walls. 6) Genetic dyslipoproteinemia: genomic determinants and functional consequences: This project, by elucidating genomic mechanisms of familial dyslipoproteinemias and the effects of these disorders upon lipoprotein interconversions and catabolism, will increase our understanding of the basis of atherogenic dyslipoproteinemias. 7) Postprandial lipid metabolism in coronary artery disease: This project will investigate abnormalities of plasma triglyceride and cholesterol transport in the postprandial state to provide new insights into the dynamic changes in metabolism of atherogenic and antiatherogenic lipoproteins after fat ingestion. The SCOR will be supported by three Core Units: a Lipid Clinic, Laboratories, and an Administrative Unit. The entire program will form a cohesive and coherent attack upon central issues of the relationship between plasma lipoproteins and atherogenesis.